Skip to main content
Clinical Trials/NCT03659513
NCT03659513
Completed
Not Applicable

Pharmacokinetics of the Drugs and Their Biological Response in ECMO Patients

University of Pennsylvania1 site in 1 country75 target enrollmentSeptember 13, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hypoxia
Sponsor
University of Pennsylvania
Enrollment
75
Locations
1
Primary Endpoint
Pharmacokinetics of the antibiotics - Maximal Serum Antibiotic Concentration
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This study will examine the pharmacokinetics of the various, routinely given antibiotics, sedatives, and opioids in patients undergoing venous-venous extra-corporal oxygenation (ECMO). Little is known about the distribution and effectiveness of antibiotics in this particular patient population.

Detailed Description

Patients with severe hypoxia that is refractory to traditional therapies are occasionally placed on venous-venous extracorporal membrane oxygenation (vv ECMO) to provide a bridge during the time when lungs alone cannot provide necessary support. This procedure is gaining prominence but it is largely unknown how medications, especially antibiotics, given to the patient on ECMO is distributed throughout the body as compared to patients without ECMO. Since the serum level of medication determines the biological activity of the drug, it is important to know if there is a difference in drug distribution between ECMO and non-ECMO patients. The investigator already collected well-established data on several antibiotics on non-ECMO as a part of FDA labeling. The study will help to determine if the concentration of currently prescribed are sufficient enough to reach their intended concentration in the study.

Registry
clinicaltrials.gov
Start Date
September 13, 2016
End Date
October 24, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient with respiratory failure undergoing ECMO.

Exclusion Criteria

  • Lack of consent
  • Age less than 18 years old
  • Hematocrit lower than 7

Outcomes

Primary Outcomes

Pharmacokinetics of the antibiotics - Maximal Serum Antibiotic Concentration

Time Frame: 24 hours

The primary outcome is the data describing the Maximal Serum Antibiotic Concentration (Cmax) of the antibiotics after the onset of infusion.This will be achieved by serial measurements of the serum antibiotic levels at discrete time points for total of 24 hours after starting antibiotics. We will calculate Cmax to demonstrate maximal concentration of the antibiotics.

Pharmacokinetics of the antibiotics - Area Under Curve (AUC)

Time Frame: 24 hours

The primary outcome is the data describing the Area Under Curve (AUC) of the antibiotics after the onset of infusion. This will be achieved by serial measurements of the serum antibiotic levels at discrete time points for total of 24 hours after starting antibiotics. We will calculate AUC to further demonstrate the distribution of antibiotic patients undergoing ECMO treatment.

Secondary Outcomes

  • Clinical effectiveness of antibiotic dosing for ECMO patients(3 months)

Study Sites (1)

Loading locations...

Similar Trials